


# MICI : nouvelles idées nouvelles thérapeutiques

Guillaume Savoye


# Les MICI sont des maladies progressives...



CDAI, Crohn's disease activity index; CDEIS, Crohn's disease endoscopic index of severity; CRP, C-reactive protein

Pariente B, ... Lemann M. Inflamm Bowel Dis 2011; Colombel JF et al. Gastroenterology 2017


# Qu'il faut traiter précocément...



CDAI, Crohn's disease activity index; CDEIS, Crohn's disease endoscopic index of severity; CRP, C-reactive protein

Pariente B, ... Lemann M. Inflamm Bowel Dis 2011; Colombel JF et al. Gastroenterology 2017

# Pour éviter la destruction intestinale et l'invalidité associée




CDAI, Crohn's disease activity index; CDEIS, Crohn's disease endoscopic index of severity; CRP, C-reactive protein

Pariente B, et al. Inflamm Bowel Dis 2011; Colombel JF et al. Gastroenterology 2017


Pariente B, et al. Inflamm Bowel Dis 2011;17:1473-22

# les anti-TNF rapidement diminuent la destruction intestinale

- 130 Crohn
  - Score de destruction intestinale



CD, Crohn's disease; IQR, interquartile range





Farre C, et al. Presented at UEG Week 2017


# La cible dans les MICI

## Rémission clinique

+




# “le contrôle serré”





CDAI, Crohn's disease activity index; CDEIS, Crohn's disease endoscopic index of severity; CRP, C-reactive protein

Pariente B, et al. Inflamm Bowel Dis 2011; Colombel JF et al. Gastroenterology 2017



# Etude CALM ou décider sur des biomarqueurs...




# On fait mieux en prenant en compte les biomarqueurs en plus de la clinique...



# Place de l'imagerie “proactive” dans le monitoring




# Des nouvelles cibles...



IL, interleukin.

Adapted from Danese S, Gut 2012 and Torres J et al. Lancet 2017


# IL-12 and IL-23 et Crohn




# Ustekinumab et Crohn

## Réponse à 6 semaines

### UNITI-1




### UNITI-2



AMM: Bolus iv

Feagin B et al. NEJM 2016

# Ustekinumab et Crohn: rémission à la 44<sup>ie</sup> semaine




AMM: entretien sc toutes les 8 ou 12 semaines



Feagn B et al. NEJM 2016

# Vedolizumab = Entyvio®

– Anti intégrine  $\alpha 4\beta 7$



Inhibition spécifique  
interaction  
 $\alpha 4\beta 7$ /MADCAM1



# • Entyvio® = Vedolizumab

AMM

et remboursement : RCH et Crohn


AMM

et remboursement : RCH et Crohn


Voie intraveineuse

Induction puis entretien 300 mg/8S


RCH S52



MC S6




MC S52



Feagan BG, *N Engl J Med* 2013;369(8):699–710  
Sandborn WJ, *N Engl J Med* 2013;369:711–721.

# L'arrivée des petites molécules par voie orale




Spadaccini M, et al. Int. J. Mol. Sci. 2017, 18, 1276

Sandborn WJ, et al. N Engl J Med 2016;374:1754–1762

Peyrin-Biroulet L, et al. Autoimmun Rev 2017;16:495–503.

# Tofacitinib, inhibiteur panJAK: Phase III dans la RCH




Nom commercial Xeljanz

AMM et remboursement dans la PR


Sandborn W, et al. N Engl J Med 2017;376:1723–1736

# Nouvelles approches : cellules souches

Des cellules souches d'origine graisseuses



Panes J et al. Nat Rev Gastroenterol Hepatol 2017



# conclusion

